Tiziana Life Sciences Ltd.: Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
FDA Provides Positive Feedback on Intranasal Foralumab Program in Patients with Non-Active SPMSFirst Phase 2 trial employing intranasal foralumab for treating inflammatory neurological diseaseTiziana received